Phosphagenics Sp ADR (PPGNY) 0.5640

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Phosphagenics Sp ADR (PPGNY) 0.5640 $PPGNY

Osteoarthritis Pain Pipeline Report 2015 - 26 Companies & 46 Drug Profiles
M2 - Fri Jul 10, 3:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w8bmth/osteoarthritis) has announced the addition of the "Osteoarthritis Pain - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Osteoarthritis Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoarthritis Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Actavis plc - Addex Therapeutics Ltd - Afferent Pharmaceuticals, Inc. - Akron Molecules AG - Amgen Inc. - Ampio Pharmaceuticals, Inc. - AnaMar AB - Antibe Therapeutics, Inc. - Astellas Pharma Inc. - Boehringer Ingelheim GmbH - Bone Medical Limited - Eli Lilly and Company - Flexion Therapeutics, Inc. - Grunenthal GmbH - iCeutica, Inc. - Iroko Pharmaceuticals, LLC - Nektar Therapeutics - Nuvo Research Inc. - Pfizer Inc. - Phosphagenics Limited - Pozen, Inc. - Purdue Pharma L.P. - Regeneron Pharmaceuticals, Inc. - Rottapharm SpA - Teva Pharmaceutical Industries Limited Drug Profiles - (lidocaine tetracaine) - A-889425 - AAT-008 - ADX-71441 - AF-219 - AKR-202 - AMAP-102 - Ampion - AQU-010 - AS-288640100 - ATB-346 - BI-1026706 - calcitonin - cebranopadol - celecoxib - CGS-125 - CRB-0022 - CRB-0089 - duloxetine hydrochloride DR - ELS-130 - fasinumab - fulranumab - FX-005 - grapiprant - ibuprofen - ibuprofen - LY-2951742 - meloxicam - naproxen sodium - NEO-5024 - NEO-6860 - NKTR-181 - OLT-1177 - onabotulinumtoxin A - oxycodone ER For more information visit http://www.researchandmarkets.com/research/w8...oarthritis
FLXN: 23.74 (+1.31), PFE: 34.36 (+0.50), AMGN: 154.10 (+2.79), AMPE: 2.51 (+0.24), LLY: 88.29 (+0.81), NKTR: 11.40 (+0.22), TEVA: 61.38 (-0.75), ABBV: 69.23 (+1.26), POZN: 10.14 (-0.25), REGN: 526.01 (+16.98)

Complicated Skin And Skin Structure Infections (cSSSI) Therapeutics Pipeline Review, H1 2015 - 7 Companies & 11 Drug Profiles
M2 - Thu Jul 09, 10:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vw27k3/complicated_skin) has announced the addition of the "Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Complicated Skin And Skin Structure Infections (cSSSI), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Complicated Skin And Skin Structure Infections (cSSSI) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Cempra, Inc. - CrystalGenomics, Inc. - Debiopharm International S.A. - Dong-A Socio Group - GlaxoSmithKline plc - Melinta Therapeutics, Inc - Phosphagenics Limited Drug Profiles - CG-400549 - Debio-1450 - Debio-1452 - delafloxacin - fusidic acid - GSK-2140944 - iclaprim mesylate - lanopepden - Small Molecule for Skin Infections - Small Molecules to Inhibit DHFR for Infectious Diseases - tedizolid phosphate For more information visit http://www.researchandmarkets.com/research/vw...cated_skin
GSK: 42.45 (+0.65), CEMP: 36.27 (+2.26)

Peripheral Neuropathic Pain - Pipeline Review, H1 2015
M2 - Mon Jun 29, 10:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9893bq/peripheral) has announced the addition of the "Peripheral Neuropathic Pain - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Peripheral Neuropathic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Neuropathic Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - AnaBios Corporation - Astellas Pharma Inc. - Eli Lilly and Company - GW Pharmaceuticals plc - Nektar Therapeutics - Pfizer Inc. - Phosphagenics Limited - Sunovion Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/9893bq/peripheral
PFE: 34.36 (+0.50), LLY: 88.29 (+0.81), NKTR: 11.40 (+0.22)

Seborrhea Pipeline Review, H1 2015 - 4 Companies & 6 Drug Profiles
M2 - Fri Jun 12, 4:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pvb5km/seborrhea) has announced the addition of the "Seborrhea - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Seborrhea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Seborrhea and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Biomar Microbial Technologies - EpiPharm AG - Maruho Co., Ltd. - Phosphagenics Limited Drug Profiles - A-101 - EPI-SK14 - IB-07A081 - IB-07A085 - ketoconazole - lanoconazole For more information visit http://www.researchandmarkets.com/research/pvb5km/seborrhea

Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 21, 10:31AM CDT
The report "Dermatitis - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Dermatitis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/dermatitis-p...eport.html .
VTAE: 10.26 (-0.25), FOMX: 11.18 (+0.22), PVCT: 0.51 (+0.01), JNJ: 99.53 (+1.13), DERM: 18.22 (+0.30), ANAC: 84.61 (+1.95), XNCR: 22.60 (+0.13), REGN: 526.01 (+16.98), AQXP: 1.94 (-0.19), BMY: 69.27 (+1.38), GSK: 42.45 (+0.65), VRX.TO: 294.65 (+11.22), CBPO: 111.03 (+7.77), MRK: 57.95 (+0.57), CCXI: 8.60 (+0.19), CLTX: 0.49 (-0.02), CELGZ: 2.15 (+0.14), NVS: 103.22 (+3.20)

Seborrhea Therapeutic Pipeline Review H2 2014 Report at ReportsnReports.com
PRWeb - Fri Jan 02, 4:30PM CST
The report "Seborrhea Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Seborrhea. Seborrhea is a common skin problem. It causes a red, itchy rash and white scales. It particularly affects the sebaceous-gland-rich areas of skin such as scalp, face and torso. Seborrhoeic dermatitis symptoms appear gradually and usually the first signs are flaky skin and scalp. Adults of all ages may develop seborrhea, too, especially on the scalp and face. Complete Report is Available @ http://www.reportsnreports.com/reports/321896...-2014.html .
VRX.TO: 294.65 (+11.22)

Phosphagenics Completes First Tranche of A$19.3 Million Capital Raising
PR Newswire - Mon Jul 21, 6:00AM CDT
Australian drug delivery company, Phosphagenics Limited (ASX: POH; OTCQX: PPGNY), today announced that it has raised A$12.2 million of its A$16.3 million capital raising program. The Company is looking to raise an additional A$3 million from a share purchase plan (SPP) to be offered to existing shareholders.

Global Transdermal Drug Delivery Market 2014-2018 with ANI Pharmaceuticals, Antares Pharma, Bayer, Janssen Pharma & Novartis Dominating
M2 - Wed Jul 16, 9:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sz2mh3/global) has announced the addition of the "Global Transdermal Drug Delivery Market 2014-2018" report to their offering. The Global Transdermal Drug Delivery market will grow at a CAGR of 9.9% Transdermal drug delivery is a large and growing vertical market of the Pharmaceutical industry. Transdermal drug delivery is defined as a system that utilizes skin as a site for continuous drug administration into the systemic circulation. Several methods of transdermal drug delivery include plasters, various ointments and, most commonly, patches. Transdermal drug administration has several advantages. First, the method of delivery is non-invasive, which is much less traumatic to the patient as compared to other forms of drug delivery. Also, it can be effective in assuring that a patient receives a full dosage of a drug and helps in increasing the compliance rate. However, there are difficulties associated with administering medication through the skin. The natural function of the skin is to act as a protective barrier, so it is often the case that drugs are not chemically suitable to penetrating the skin. This report covers the present scenario and the growth prospects of the Global Transdermal Drug Delivery market for the period 2013-2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs administered transdermally and proprietary transdermal technologies available in the market. The Global Transdermal Drug Delivery market can be divided into five segments: - Smoking Cessation - Pain Management - Hormone Therapy - Cardiovascular Indications - Others Key Vendors - ANI Pharmaceuticals Inc. - Antares Pharma Inc. - Bayer AG - Janssen Pharmaceuticals Inc. - Novartis AG Other Prominent Vendors - 3M Pharmaceuticals Co. - Durect Corp. - Iontera Inc. - Isis Biopolymer Inc. - LTS Lohmann Therapie-Systeme AG - Mylan Laboratories Inc. - Nitto Denko Corp. - Pantec Biosolutions AG - Phosphagenics Ltd. - Tesa Labtec GmbH - Teva Pharmaceutical Industries Ltd. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Competitive Assessment of Transdermal Drugs Delivery Market - Optimisation of Transdermal Drug Delivery - Market Segmentation by Application - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/sz2mh3/global
ANIP: 62.22 (+1.36), MYL: 71.22 (+0.87), TEVA: 61.38 (-0.75), DRRX: 2.48 (+0.15), ATRS: 2.26 (+0.09), NVS: 103.22 (+3.20)

Global Anti-Aging Product Market 2014-2018 - Skincare Products, Cosmeceuticals, and Hair Care Products
M2 - Wed Jul 16, 8:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7slrvw/global_antiaging) has announced the addition of the "Global Anti-Aging Product Market 2014-2018" report to their offering. The Global Anti-aging Product market will grow at a CAGR of 6.77 percent over the period 2013-2018. Aging is associated with numerous common health problems. Anti-aging products help in fighting the various signs of aging or problems such as wrinkles, blemishes, dry lines, fine color, pores, graying, thinning, and sagging. To overcome these aging problems related to skin and hair consumers use many products that basically fall under three categories: skincare, cosmeceuticals, and hair care. The Global Anti-aging Product market can be divided into three segments: Skincare Products, Cosmeceuticals, and Hair Care Products. These are the product categories used by consumers to reduce various signs of aging and maintain youthfulness. The report, the Global Anti-aging Product Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Anti-aging Product market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Vendors - Beiersdorf AG - L'Or?al SA - Phosphagenics Ltd. - Procter & Gamble Co. - Unilever Group Other Prominent Vendors - Allergan Inc. - Amexdrug Corp. - Avon Products Inc. - Chanel SA - Christian Dior SA - Clarins USA Inc. - DS Healthcare Group Inc. - Elizabeth Arden Inc. - Ella Bach? - Est?e Lauder Co. Inc. - Henkel AG & Co KGaA - Jan Marini Skin Research Inc. - Johnson & Johnson Co. - Kao Corp. - NeoStrata Co. - NuSKin Enterprises - Orlane SA - Revlon Inc. - Robanda International Inc. - Shiseido Co. - SkinMedica Inc. - Skinvisible Inc. - Woodridge Labs Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Demographic Segmentation - Market Segmentation by Product - Geographical Segmentation - Key Leading Countries - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/7s..._antiaging
REV: 36.32 (+0.50), AVP: 5.90 (-0.07), RDEN: 12.16 (-0.27), DSKX: 3.18 (-0.05), AGN: 312.13 (+8.03), JNJ: 99.53 (+1.13), PG: 80.95 (+0.29)

Phosphagenics' A$19.3 million Capital Raising
PR Newswire - Fri Jul 11, 8:30AM CDT
Australian drug delivery company, Phosphagenics Limited (ASX: POH; OTCQX: PPGNY), today announced that it has raised A$19.3 million via a placement of A$16.3 million to institutional investors in Europe, the U.S., Asia and Australia and A$3 million from a share purchase plan (SPP) to be offered to existing shareholders. The placement of A$16.3 million will be made in two tranches.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ELEGOO's Formnext Push Tests a Broader 3D Ambition

Updated Category News Views 75

Frankfurt’s show floor is where product promises meet some very unforgiving eyeballs. ELEGOO arrived at Formnext 2026 with more than a refreshed machine or two: it is laying out a wider bet across resin printing, FDM printing, and 3D scanning. That matters because the company is no longer presenting itself as merely a supplier of affordable creator hardware. It wants to...

Continue Reading
Inhibrx Ewing Data Gives Ozekibart a Real Clinical Signal

Updated Category News Views 102

Numbers this lopsided in relapsed Ewing sarcoma make me sit up straight, even after years of watching oncology releases try to turn every blip into a brass band. Inhibrx has reported updated Phase 1/2 data for ozekibart, paired with irinotecan and temozolomide, that look genuinely notable in a disease where patients have very few good cards left to play. That matters...

Continue Reading
Aurora Innovation Faces Legal Probe After Stock Plunge

Updated Category News Views 80

Aurora's Troubles Draw Legal Scrutiny Looks like Aurora Innovation’s in the hot seat again, and not in a good way. When you see Kessler Topaz Meltzer & Check, LLP throwing their name into the mix, you know it’s getting serious. This legal eagle firm is poking around, seeing if Aurora stepped over the line with investors after their latest stumble—a production delay...

Continue Reading
Wonder Create: Democratizing Restaurant Creation

Updated Category News Views 112

Breaking Down Barriers in the Restaurant Industry It's been a long time since someone truly shook up the restaurant scene like this. Wonder Create is stepping in to turn anyone with a wild food idea into a bonafide restaurateur. We're not talking about the ol' franchising route here. We're diving straight into democratizing the culinary world. You seen something this bold...

Continue Reading
Universal Haptics Protocol May Cut Integration Friction

Updated Category News Views 291

A controller rumbling at the wrong moment is a small annoyance, but the plumbing behind that rumble has been a stubborn mess for years. The Haptics Industry Forum's Universal Haptics Protocol 1.0, announced November 17, 2026, is an attempt to clean up that mess with a shared language between software and touch-feedback hardware. This is not the sort of release that sends...

Continue Reading
MAXHUB's Canon Office Test Puts Hybrid Work on Trial

Updated Category News Views 22

Thirty-nine devices scattered through a new Hong Kong office may not sound earth-shaking, but this is how workplace technology actually earns its keep: not under trade-show lights, but when somebody is late to a meeting in another time zone and the room has to work anyway. MAXHUB and Canon Hong Kong have launched the first officially delivered Co-Create 100 project...

Continue Reading
STORMER LAT Targets Sewer Crews' Costly Access Delays

Updated Category News Views 65

A buried cleanout can turn a simple sewer inspection into a scheduling circus. That unglamorous headache is exactly where FIBERSCOPE is aiming its new STORMER LAT Lateral Launch Camera System, announced November 17, 2026. This is not some flashy consumer gadget hunting for attention; it is field equipment built around a painfully ordinary municipal problem: crews often...

Continue Reading
InPHRED's Award Brings 1310 nm VCSELs Into Focus at IEEE

Updated Category News Views 64

A stubborn mirror problem just put InPHRED on the photonics map. InPHRED, founded in 2023, took the Best Technology award at the inaugural 2026 IEEE Photonics Conference Start-Up Competition, selected from seven finalists. That is a meaningful industry pat on the back, particularly because the company is aiming at a real engineering headache rather than waving around...

Continue Reading
Hanon's BMW Thermal Win Matters Beyond the Trophy Case Today

Updated Category News Views 11

A 16-Kilogram Box Just Grabbed the Auto Supply Chain’s Attention Hanon Systems did not win these two 2026 PACE honors by polishing up some old hose-and-valve package. Its Highly Integrated Cooling Entity, or HICE, is aimed right at a stubborn electric-vehicle problem: keeping a vehicle’s thermal systems controlled without turning the architecture into a sprawling,...

Continue Reading
Madrigal Pharmaceuticals Faces Legal Scrutiny Over Data

Updated Category News Views 71

Legal Storm Brews for Madrigal Pharmaceuticals Watch out, here comes another storm for Madrigal Pharmaceuticals, folks. This ain't no small drizzle either; it's a full-on legal monsoon, and it's soaked straight through the walls of their executive suite. We're talking a whistleblower sending alarm bells ringing about data fudging and some dodgy boardroom maneuvers—as if...

Continue Reading

Top 5 Most Recently Viewed Articles

VICTOR Pet Food Launches New Line for Sensitive Dogs and Puppies

Updated Category News Views 313

VICTOR Pet Food Launches New Line for Sensitive Dogs and Puppies VICTOR Super Premium Pet Food, known for its dedication to high-quality pet nutrition, is proud to unveil a new line aimed specifically at canines with sensitive skin and stomach issues. The Sensitive Skin and Stomach line is designed to meet the dietary needs of both adult dogs and puppies, and will be...

Continue Reading
Exploring the Growth of the Pressure Monitoring Market

Updated Category News Views 181

The Expanding Pressure Monitoring Market This flourishing sector is gaining significant traction, reflecting a market valued at approximately US$13.63 billion in 2024, with a current rise to US$14.56 billion in 2025. The forecast indicates a notable compound annual growth rate (CAGR) of 8.3% from this point through 2032, culminating in an anticipated valuation of US$25.48...

Continue Reading
Citadel Credit Union Champions Community Engagement Initiatives

Updated Category News Views 636

Citadel Credit Union's Commitment to Community Support Citadel Credit Union is dedicated to reaffirming its commitment to its members and the surrounding region through an innovative approach to philanthropy. The organization has escalated its focus on community partnerships and employee-driven initiatives, making strides toward becoming a leader in promoting meaningful...

Continue Reading
TRIMEDX Bolsters Leadership with New Chief Data & AI Officer

Updated Category News Views 163

TRIMEDX Elevates Leadership with a Visionary Hire Indianapolis—TRIMEDX, a leading name in independent clinical asset management, is taking substantial strides in enhancing its technological offerings. The company has recently welcomed Srilekha Akula as its Chief Data & AI Officer. Her arrival marks a pivotal moment in TRIMEDX's journey, aimed at fostering innovation and...

Continue Reading
Exploring the Leadership of Ford as a Dividend Powerhouse

Updated Category News Views 170

Ford Motor Company (NYSE: F) has been a staple name in the automotive sector, but it’s got some serious hurdles to jump over. The stock price took a 12% nosedive over the past year, and while that might raise eyebrows, it also sets the stage for potential dividend plays. The price-to-earnings ratio is sitting pretty low at 11—sounds tempting for those looking at...

Continue Reading